重构自身的发展路径。《投资者网》蔡俊7月，中国生物制药（01177.HK，下称“公司”）又发起收购。根据公告，公司将收购礼新医药。该标的主营创新药研发，此前与海外大厂签署合作协议。因此，该笔交易也被视为公司转型创新药的重要关键点。如今，公司的市值迈进千亿，一年不到也发起两笔重要收购。从业务到资本价值，公司正重构自身的发展路径。但如同海尔集团发展史上的经典三问，涵盖业务模式、股权、商业生态等，市场对...
Source Link重构自身的发展路径。《投资者网》蔡俊7月，中国生物制药（01177.HK，下称“公司”）又发起收购。根据公告，公司将收购礼新医药。该标的主营创新药研发，此前与海外大厂签署合作协议。因此，该笔交易也被视为公司转型创新药的重要关键点。如今，公司的市值迈进千亿，一年不到也发起两笔重要收购。从业务到资本价值，公司正重构自身的发展路径。但如同海尔集团发展史上的经典三问，涵盖业务模式、股权、商业生态等，市场对...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.